ZYTO is a global technology company. We develop and produce software and integrated hardware products that have been specifically designed to provide insight into personal health and wellness decisions. ZYTO products accomplish this goal by using ZYTO scan technology.
The innovative ZYTO scan technology facilitates an interface between a computer and the human body. The resulting dynamic data exchange, known as a biosurvey, involves computer generated signatures called "virtual stimuli" and recording the body's Galvanic skin response, a well-developed method of monitoring stress responses that is commonly used in applications like polygraph tests and biofeedback.
By recording and correlating responses to specific virtual stressors, health professionals are able to narrow their focus, paying particular attention to areas where diagnostic tests should be run or where clinical therapy should be applied. Biosurveys are designed to help clinicians make better decisions and achieve better, more efficient clinical outcomes.
ZYTO technology does not identify, diagnose or treat any disease or medical condition.
In 1985 Dr. Vaughn Cook (founder and CEO of ZYTO) went to work for the Esion Corporation, the maker of the Interro biocommunication device. During Dr. Cook’s time at Esion he worked in both sales and training and became familiar with every aspect of technology-based biocommunication. In 1988 Dr. Cook left Esion to start a company named Digital Health Corp. There he developed an innovative computerized EAV system he called the Omega AcuBase. The Omega AcuBase was the first system of its kind to be registered with the U.S. Food and Drug Administration (FDA).
In 1997 Dr. Cook sold this technology to the BioMeridian Corporation, and for a short time worked for BioMeridian in sales, training, and eventually as its President. However, in 1998 Dr. Cook left BioMeridian, choosing instead to focus his efforts on Digital Health’s core business.
In 2001 Dr. Cook independently began development of what is now ZYTO technology, and began selling the technology in late 2004 through Digital Health. At the end of 2004 he organized Zyto NV, and transferred his technology to the new organization including the ZYTO Hand Cradle and Tower, the initial software package, and the methods for programming computerized stimuli known as Virtual Stimulus Items (VSI).
Under the direction of Dr. Cook, ZYTO has continuously pursued product enhancements, further development of the technology, and a commitment to meeting the needs of our users. During the intervening years we have released three new versions of the software and developed new market specific applications, such as the ZYTO Compass. We have also redesigned the original hardware, including upgrading the Hand Cradle with a cleaner, sleeker look and USB functionality. More exciting innovations are to come.
During the last 25 years Dr. Cook has been continuously involved in the development and sale of biocommunication technology. During this time he has also been actively involved in clinical practice as the owner of Utah Acupuncture Clinic and the Meridian Health Center in Salt Lake City, Utah. This clinical experience has strongly influenced the technology that Dr. Cook has developed and continues to develop in order to meet the changing needs of our customers.
For an history of biocommunication Click Here
Vaughn R Cook founded ZYTO and has served as Chairman of the Board and Chief Executive Officer since its incorporation in December of 2004. He has been employed full time by ZYTO since its inception. Dr. Cook is an honors graduate of Utah State University, has an acupuncture degree from the Oriental Medical Institute of Hawaii, and an OMD (Oriental Medical Doctor) degree from the North American Academy of Advanced Asian Medicine. He is board certified and licensed as an acupuncturist in Utah. For nearly thirty years Dr. Cook has worked in the Complementary and Alternative Medical field. He has specialized in technology applications that integrate western and eastern medicine. He has worked for Esion Corp, the company that developed the Interro; has been the President and owner of Digital Health Corp, the company that developed the Omega Acubase System; and President of BioMeridian International, Inc., the company that developed the MSA Pro and other related technology. He has developed multiple computer-based systems used by healthcare professionals around the world. The first was the Omega AcuBase System, and the most recent is ZYTO technology. Concurrent with his work with technology, Dr. Cook owned and operated the Utah Acupuncture Clinic and the Meridian Health Center in Salt Lake City, Utah. This clinical background has allowed him to develop equipment from the perspective of a practicing healthcare professional, which combined with an extensive background in business, has resulted in technology that is clinically effective and financially practical. He has traveled extensively and taught principles of alternative medicine throughout the United States and in many countries.
Kami J. Howard joined ZYTO in April 2007 as the Chief Financial Officer and was first elected to serve as a director of the Company in October 2008. Ms. Howard was elected by our Board of Directors to serve as our Secretary on June 27, 2010 and in March 2011 was appointed by the Board of Directors to serve as the Company's President and Chief Operating Officer. As a member of our senior management team she is involved in strategic planning and is responsible for all financial, regulatory, and investor relation aspects of the business.
Prior to joining ZYTO, Ms. Howard spent five years at Browz, LLC, a technology company specializing in supply chain verification, where she served as Vice President and Company Controller for the entire length of her employment. Her responsibilities included accounting, business and tax planning on behalf of the LLC and its members. From 2000 to 2003, Ms. Howard served as Vice President and Corporate Controller for BioMeridian Corporation and its subsidiaries. Prior to her appointment at BioMeridian, Ms. Howard served in various senior financial positions. She holds a B.S. in accounting and a Master's Degree in Business Administration. Recently she received the Stevie Award for her accomplishments.
Hammad M. Shah was first elected to serve as a director of ZYTO in October 2008 and currently serves as the president of FreseniusRx. Mr. Shah champions the company’s vision to change the practice of pharmacy from simply dispensing medications to playing an integral role in patient care. His direction positions FreseniusRx to drive improved patient outcomes by connecting clinical, pharmacy and lab data to provide physicians with a complete view of each patient’s overall health.
Since joining FreseniusRx in 2012, Mr. Shah has created a growth strategy that transformed the previously full-service pharmacy into a renal specialty pharmacy, providing health care expertise to patients living with kidney disease. FreseniusRx encourages increased medication adherence, striving to decrease patient hospitalization, reduce health care costs and achieve quality patient care. Under his leadership, FreseniusRx grew from double-digit revenue to tripledigit revenue in just two and a half years. In his role, Mr. Shah also serves as a senior vice president for Fresenius Medical Care North America, parent company of FreseniusRx, to bridge the company’s pharmacy services with the larger renal division.
Mr. Shah, a registered pharmacist, has more than 20 years of experience in health care leadership, serving in senior administrative, strategic and operational roles. His business experience crosses many disciplines including product development, Medicaid, start-ups, sales, process improvement, and mergers and acquisitions.
Prior to joining FreseniusRx, he served as vice president and general manager for emerging markets at Express Scripts. He was responsible for managing a portfolio of companies, as well as supporting an acquisition strategy designed to meet inorganic, domestic health care growth goals.
Mr. Shah’s experience in health care leadership spans the globe including work in Asia and Europe during a time where specific countries in those regions, such as China, Singapore, Germany and the United Kingdom, were undergoing significant efforts to reform their health care systems. This has given him the deep expertise required to aid organizations in understanding how to operate in a rapidly changing health care market.
He carries his passion for delivering data-driven solutions beyond FreseniusRx. Mr. Shah also sits on the board of directors for Remedi Senior Care, which provides pharmacy solutions that enable long-term care facilities to reduce medication costs, improve efficiency and increase medication administration safety and accuracy.
Mr. Shah attended Arizona State University, where he earned a master’s degree in business administration and completed coursework toward a master’s degree in health sector management. He holds a bachelor’s degree in pharmacy from Temple University.